WO2011093818A3 - Pharmaceutical compositions comprising salmeterol and fluticasone - Google Patents

Pharmaceutical compositions comprising salmeterol and fluticasone Download PDF

Info

Publication number
WO2011093818A3
WO2011093818A3 PCT/TR2011/000020 TR2011000020W WO2011093818A3 WO 2011093818 A3 WO2011093818 A3 WO 2011093818A3 TR 2011000020 W TR2011000020 W TR 2011000020W WO 2011093818 A3 WO2011093818 A3 WO 2011093818A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical compositions
salmeterol
fluticasone
pharmaceutically acceptable
treatment
Prior art date
Application number
PCT/TR2011/000020
Other languages
French (fr)
Other versions
WO2011093818A2 (en
Inventor
Mahmut Bilgic
Original Assignee
Mahmut Bilgic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mahmut Bilgic filed Critical Mahmut Bilgic
Publication of WO2011093818A2 publication Critical patent/WO2011093818A2/en
Publication of WO2011093818A3 publication Critical patent/WO2011093818A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to pharmaceutical compositions in dry powder form comprising salmeterol xinafoat and fluticasone propionate and/or their pharmaceutically acceptable derivatives as active agents, and capsule forms containing these pharmaceutical compositions so as to be used in treatment of respiratory tract diseases.
PCT/TR2011/000020 2010-01-29 2011-01-28 Pharmaceutical compositions comprising salmeterol and fluticasone WO2011093818A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2010/00685A TR201000685A2 (en) 2010-01-29 2010-01-29 Pharmaceutical preparations containing salmeterol and fluticasone.
TR2010/00685 2010-01-29

Publications (2)

Publication Number Publication Date
WO2011093818A2 WO2011093818A2 (en) 2011-08-04
WO2011093818A3 true WO2011093818A3 (en) 2012-02-23

Family

ID=44141818

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2011/000020 WO2011093818A2 (en) 2010-01-29 2011-01-28 Pharmaceutical compositions comprising salmeterol and fluticasone

Country Status (2)

Country Link
TR (1) TR201000685A2 (en)
WO (1) WO2011093818A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2494730C1 (en) * 2012-03-27 2013-10-10 Шолекс Девелопмент Гмбх Inhalation preparation for treating respiratory diseases containing micronised salmeterol xinafoate and micronised fluticasone propionate as active substances and method for preparing it
MX361886B (en) 2012-05-08 2018-12-18 Nicox Ophthalmics Inc Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof.
US8765725B2 (en) 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
US9815865B2 (en) 2013-01-07 2017-11-14 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
WO2014202513A1 (en) * 2013-06-17 2014-12-24 Arven Ilac Sanayi Ve Ticaret A.S. Inhalation composition filling method
WO2022045994A1 (en) * 2020-08-28 2022-03-03 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi A process for the preparation of dry powder compositions for inhalation

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001028535A2 (en) * 1999-10-21 2001-04-26 Glaxo Group Limited Pharmaceutical formulations comprising a combination of s-salmeterol and fluticasone propionate
WO2002069979A2 (en) * 2001-03-07 2002-09-12 Glaxo Group Limited Pharmaceutical formulation comprising r-salmeterol and fluticasone propionate
US20030018019A1 (en) * 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
WO2003033000A1 (en) * 2001-10-12 2003-04-24 Glaxo Group Limited Pharmaceutical combinations comprising salmeterol and fluticasone proprionate for the treatment of asthma
US20070053843A1 (en) * 2003-10-28 2007-03-08 Dawson Michelle L Inhalable pharmaceutical formulations employing lactose anhydrate and methods of administering the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56138200A (en) 1980-02-15 1981-10-28 Glaxo Group Ltd Androstane carbothioate compound
ZW6584A1 (en) 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001028535A2 (en) * 1999-10-21 2001-04-26 Glaxo Group Limited Pharmaceutical formulations comprising a combination of s-salmeterol and fluticasone propionate
WO2002069979A2 (en) * 2001-03-07 2002-09-12 Glaxo Group Limited Pharmaceutical formulation comprising r-salmeterol and fluticasone propionate
US20030018019A1 (en) * 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
WO2003033000A1 (en) * 2001-10-12 2003-04-24 Glaxo Group Limited Pharmaceutical combinations comprising salmeterol and fluticasone proprionate for the treatment of asthma
US20070053843A1 (en) * 2003-10-28 2007-03-08 Dawson Michelle L Inhalable pharmaceutical formulations employing lactose anhydrate and methods of administering the same

Also Published As

Publication number Publication date
TR201000685A2 (en) 2011-08-22
WO2011093818A2 (en) 2011-08-04

Similar Documents

Publication Publication Date Title
WO2012016889A3 (en) Dry powder formulation comprising a phosphodiesterase inhibitor
IL223783B (en) Substituted 1-indole compound for use in the treatment of a disease or condition, a pharmaceutical composition comprising the compound and use of the compound for the preparation of a medicament
TN2012000566A1 (en) Dry powder formulation comprising an antimuscarinic drug
JP2010132695A5 (en)
IL216741A (en) 1,3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating diseases
WO2011112229A3 (en) Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
WO2012021715A3 (en) Stable formulations of linaclotide
TR201000680A2 (en) Pharmaceutical compositions containing tiotropium, formoterol and budesonide
WO2013183062A3 (en) Palatable formulations of ibuprofen
WO2011086093A3 (en) Pharmaceutical compositions for oral administration of insulin peptides
WO2014016548A3 (en) Pharmaceutical composition comprising olodaterol and one or more further active pharmaceutical ingredient
TR201000681A2 (en) Dry powder formulations inhaled.
WO2011093818A3 (en) Pharmaceutical compositions comprising salmeterol and fluticasone
TR201000733A2 (en) Pharmaceutical compositions comprising fluticasone, tiotropium and sodium chromoglycate.
WO2011093815A3 (en) Pharmaceutical compositions comprising formoterol and mometasone
WO2011152804A3 (en) Process for dry powder formulations
IL213671A (en) Pharmaceutical compositions comprising aleglitazar, process for their manufacture and use thereof in the preparation of medicaments
IL210386A (en) Indole derivatives, pharmaceutical compositions comprising same and use thereof for preparing medicaments for the treatment or prevention of neurodegenerative diseases
WO2011101734A3 (en) Taste-masked powder for suspension compositions of methylprednisolone
IL210975A (en) Enfumafungin derivatives, pharmaceutical compositions comprising them and use thereof for the preparation of medicaments for treating fungal infections
IL217519A (en) Tazarotene derivatives, pharmaceutical compositions comprising them and use thereof for the manufacture of medicaments for the treatment of skin disorders
WO2011093811A3 (en) Pharmaceutical preparations comprising formoterol and fluticasone
WO2011139249A3 (en) Pharmaceutical composition comprising cefdinir
WO2012030308A3 (en) Formulation comprising cellobiose
WO2011093812A3 (en) Pharmaceutical formulation comprising tiotropium and budesonide in dry powder form

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11712062

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11712062

Country of ref document: EP

Kind code of ref document: A2